1. Epilepsy. World Health Organization.
http://www.who.int/topics/epilepsy/en/.
Accessed Sep. 18th, 2014.
2. NICE clinical guideline 137 - The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care.
National Institute for Health and Care Excellence.
http://www.nice.org.uk/guidance/cg137. Published 2013. Accessed Sep. 17th,
2014.3. Robert S. Fisher, Carlos Acevedo, Alexis Arzimanoglou, et al. A practical clinical definition of epilepsy. Epilepsia 2014; 55(4): 475-482.
4. J. A. French, A. M. Kanner, J. Bautista ea. Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62.
5. J. A. French, A. M. Kanner, J. Bautista ea. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the therapeutics and technology assessment subcommittee and quality standards subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62.
6. Tracy Glauser, Elinor Ben-Menachem, Blaise Bourgeois, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013; **(*):
1-13.
7. Philip N. Patsalos, David J. Berry, Blaise F. D. Bourgeois, et al. Antiepileptic drugs—best practice guidelines for therapeutic drug monitoring: A position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49(7): 1239-1276.
8. Seizures. Johns Hopkins Medicine.
http://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/epil epsy/seizures/. Accessed Sep. 18th 2014.
9. 癲 癇 症 . 台 北 榮 民 總 醫 院 神 經 醫 學 中 心 .
http://www.vghepilepsy.idv.tw/contents/7-3.htm. Accessed Sep. 18th 2014.
10. Andreas V. Alexopoulos, Eelco Wijdicks and Stephen D. Sisson. Epilepsy in adults.
https://www.clinicalkey.com/#!/ContentPlayerCtrl/doPlayContent/21-s2.0-101
6545/{"scope":"all","query":"epilepsy"}. Published 2011. Accessed.
11. Katie McPeak, Gloria Galloway and John B. Bodensteiner. Epilepsy in children.
https://www.clinicalkey.com/#!/ContentPlayerCtrl/doPlayContent/21-s2.0-101
6546/{"scope":"all","query":"epilepsy"}. Published 2010. Accessed.
12. Lee Goldman and Andrew I. Schafer. Goldman's Cecil Medicine - The Epilepsies. Twenty-Fourth ed: Elsevier Inc.; 2012.
13. Robert B. Daroff, Gerald M. Fenichel, Joseph Jankovic and John C.
Mazziotta. Bradley’s Neurology in Clinical Practice Sixth ed: Elsevier Inc.;
2012.
14. ATC/DDD Index. WHO Collaborating Centre for Drug Statistics Methodology.
http://www.whocc.no/atc_ddd_index/?code=N03AX. Accessed Sep. 17th,
2014.15. 西藥、醫療器材、含藥化妝品許可證查詢. 衛生福利部食品藥物管理署.
http://www.fda.gov.tw/MLMS/(S(qzuhhz45hilotv55foahuw45))/H0001.aspx.
Accessed Sep. 17th 2014.
16. 健 保 用 藥 品 項 查 詢 . 衛 生 福 利 部 中 央 健 康 保 險 署 .
http://www.nhi.gov.tw/query/query1.aspx?menu=21&menu_id=713&webdata _id=3510&WD_ID=851. Accessed Sep. 17th 2014.
17. 藥 品 給 付 規 定 . 衛 生 福 利 部 中 央 健 康 保 險 署 .
http://www.nhi.gov.tw/webdata/webdata.aspx?menu=21&menu_id=713&web data_id=2919. Published 2014. Accessed Sep. 17th 2014.
18. 張 揚 沛 醫 師 . 認 識 重 積 癲 癇 . 高 醫 神 經 科 暨 腦 中 風 加 護 室 .
http://www.kmuh.org.tw/www/kmcj/data/10209/11.htm.
Published 2013.Accessed Sep. 23th, 2014.
19. Common Drug Review - Perampanel. Canadian Agency for Drugs and Technologies in Health.
http://www.cadth.ca/en/search?q=perampanel.
Published 2013. Accessed Sep. 15th 2014.
20. 2014 PBAC Meeting - Positive Recommendations Australian Government
Department of Health.
www.pbs.gov.au/indus...ive%20recommendations%20consolidated.docx - 76k
docx Published 2014. Accessed Sep. 15th 2014.21. Partial-onset seizures in epilepsy: perampanel as adjunctive treatment (ESNM7) National Institute for Health and Care Excellence.
http://www.nice.org.uk/Advice/ESNM7. Published 2012. Accessed Sep. 15th
2014.22. SMC Advice - perampanel (Fycompa). Scottish Medicines Consortium.
http://www.scottishmedicines.org.uk/SMC_Advice/Advice/819_12_perampan
el_Fycompa/perampanel_Fycompa. Published 2012. Accessed Sep. 15th 2014.
23. EMA Assessment Report - Fycompa. Euroopean Medicines Agency.
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medici nes/002434/human_med_001572.jsp&mid=WC0b01ac058001d124. Published
2012. Accessed Sep. 15th 2014.24. FDA Fycompa Label. U.S. Food and Drug Administration.
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202834Orig1s000T OC.cfm. Published 2012. Accessed Sep. 15th 2014.
25. Medical Review(s) - Fycompa(perampanel) tablets. U.S. Food and Drug Administration.
http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202834Orig1s000T OC.cfm. Published 2012. Accessed Sep. 25th, 2014.
26. Primary Generalized Epilepsy. NYU Langone Medical Center.
http://epilepsy.med.nyu.edu/epilepsy/types-epilepsy/primary-generalized-epile psy#sthash.NxjCsBUq.dpbs. Accessed Sep. 25th 2014.
27. Huang J, Xiao Y, Luo M, Luo H, Wang J. Perampanel add-on for drug-resistant partial epilepsy. Cochrane Database of Systematic Reviews 2014; (2). DOI: 10.1002/14651858.CD010961. Available from:
http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010961/abstract.
28. Hsu W, Sing C, He Y, Worsley A, Wong I, Chan E. Systematic review and meta-analysis of the safety of perampanel in the treatment of partial-onset epilepsy. Drug Safety 2013; 36(9): 854-855.
29. Khan N, Shah D, Tongbram V, Verdian L, Hawkins N. The efficacy and tolerability of perampanel and other recently approved/third generation anti-epileptic drugs for the treatment of refractory partial onset seizure: a systematic review and Bayesian network meta-analysis (Provisional abstract).
Current Medical Research and Opinion 2013; 29(8): 1001-1013. Available
from:http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE-12013027863/
frame.html.
30. perampanel (Fycompa)(Structured abstract). Health Technology Assessment
Database
2013; (3). Available from:http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32013000687/fra me.html.
31. CADTH. Perampanel (Fycompa - Eisai Ltd.) indication: epilepsy, partial-onset seizures (Structured abstract). Health Technology Assessment Database 2013;
(3). Available from:
http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32014000877/fra
me.html.
32. Perampanel for epilepsy - adjunctive (Structured abstract). Health Technology
Assessment Database
2011; (3). Available from:http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32011001067/fra me.html.
33. IQWIG. Perampanel - Benefit assessment according to 35a Social Code Book V (dossier assessment) (Structured abstract). Health Technology Assessment
Database
2012; (3). Available from:http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32013000397/fra me.html.
34. NIHR HSC. Perampanel for adjuvant treatment of primary generalised tonic-clonic seizures (Structured abstract). Health Technology Assessment
Database
2014; (3). Available from:http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA-32014000584/fra me.html.
35. ClinicalTrials.gov - Search for Studies. U.S. National Institutes of Health.
http://clinicaltrials.gov/ct2/home. Accessed Sep. 29th, 2014.
36. Kramer LD, Satlin A, Krauss GL, et al. Perampanel for adjunctive treatment of partial-onset seizures: A pooled dose-response analysis of phase III studies.
Epilepsia 2014; 55(3): 423-431.
37. French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: Results of randomized global phase III study 305. Epilepsia 2013; 54(1): 117-125.
38. Rektor I, Krauss GL, Bar M, et al. Perampanel Study 207: Long-term open-label evaluation in patients with epilepsy. Acta Neurologica
Scandinavica 2012; 126(4): 263-269.
39. French JA, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: Randomized phase III study 304. Neurology 2012;
79(6): 589-596.
40. Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306 Adjunctive perampanel for refractory partial-onset seizures. Neurology 2012;
78(18): 1408-1415.
41. Hsu WWQ, Sing CW, He Y, Worsley AJ, Wong ICK, Chan EW. Systematic review and meta-analysis of the efficacy and safety of perampanel in the treatment of partial-onset epilepsy. CNS Drugs 2013; 27(10): 817-827.
42. Gidal BE, Ferry J, Majid O, Hussein Z. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
Epilepsia 2013; 54(8): 1490-1497.
43. Steinhoff BJ, Ben-Menachem E, Ryvlin P, et al. Efficacy and safety of
adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia 2013; 54(8): 1481-1489.
44. Krauss GL, Perucca E, Ben-Menachem E, et al. Perampanel, a selective, noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures:
interim results from phase III, extension study 307. Epilepsia 2013; 54(1):
126-134.
45. Krauss GL, Bar M, Biton V, et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand 2012; 125(1): 8-15.
46. Aneja S, Sharma S. Newer anti-epileptic drugs. Indian pediatrics 2013; 50(11):
1033-1040.
47. Zaccara G, Giovannelli F, Cincotta M, Verrotti A, Grillo E. The adverse event profile of perampanel: meta-analysis of randomized controlled trials.